person · Reporting owner

Jacques Rachelle Suzanne

Disclosed activity across 4 companies

Tapewire entity: 38561
SEC CIK: 0001772610

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akari Therapeutics PlcAKTX · Entity 7692	Director · Chief Executive Officer	April 26, 2024	May 01, 2024
Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261	Director	May 19, 2026	May 21, 2026
uniQure N.V.QURE · Entity 4162	Director	June 10, 2026	June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akari Therapeutics Plc

Report date April 26, 2024 · Filed May 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value $0.0001 per shareSEC Table I · non-derivative	Direct	1,018,027,792	Reported balance After 2024-04-26 transaction · row 1 1 source row Row 1 · 2024-04-26 · Grant · Acquired 479,569,892 · Balance 1,018,027,792 F1: These shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive one ordinary share, par value $0.0001. 50% of the RSUs shall vest on March 28, 2025, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive one ordinary share, par value $0.0001. 50% of the RSUs shall vest on March 28, 2025, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Corbus Pharmaceuticals Holdings, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001 per shareSEC Table I · non-derivative	Direct	11,383	Reported balance After 2026-05-19 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 3,800 · Balance 11,383 F1: On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2: This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.
Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.15 · Expires 2026-05-19	Direct	12,300	Reported balance After 2026-05-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-19 · Grant · Acquired 12,300 · Balance 12,300 F3: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

F2: This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.

F3: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.

uniQure N.V.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	33,903	Ending reported balance After 2026-06-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-10 · Grant · Acquired 7,550 · Balance 35,896 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 2 · 2026-06-11 · Sale · Disposed 1,993 · Balance 33,903 F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10	Direct	13,980	Reported balance After 2026-06-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.

F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Viela Bio, Inc.

Report date March 15, 2021 · Filed March 15, 2021

Section 16 reporting ended · disclosed 2021-03-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.96 · Expires 2030-06-18	Direct	0	Reported balance After 2021-03-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-03-15 · Disposition to issuer · Disposed 14,716 · Balance 0 F1: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.96 · Expires 2030-06-18	Direct	0	Reported balance After 2021-03-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-03-15 · Disposition to issuer · Disposed 7,358 · Balance 0 F1: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.

F2: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 11, 2026 Filed Jun 12, 2026 21:15 UTC	uniQure N.V. QURE · Entity 4162	SaleOrdinary Shares	1,993	$27.06	$53,930.58	Disclosure SEC source: 0000904454-26-000339 · edgar.xml · nonDerivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,903 F2 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:15 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	13,980	$0.00 Strike: $26.82	$0.00	Disclosure SEC source: 0000904454-26-000339 · edgar.xml · derivative · entry 3 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,980 Underlying: Ordinary Shares · 13,980 shares Expires 2036-06-10 F4 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
June 10, 2026 Filed Jun 12, 2026 21:15 UTC	uniQure N.V. QURE · Entity 4162	GrantOrdinary Shares	7,550	$0.00	$0.00	Disclosure SEC source: 0000904454-26-000339 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,896 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
May 19, 2026 Filed May 21, 2026 21:06 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock options (right to buy) · Derivative	12,300	$0.00 Strike: $9.15	$0.00	Disclosure SEC source: 0001193125-26-234857 · ownership.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,300 Underlying: Common Stock · 12,300 shares Expires 2026-05-19 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document
May 19, 2026 Filed May 21, 2026 21:06 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantCommon Stock, par value $0.0001 per share	3,800	$0.00	$0.00	Disclosure SEC source: 0001193125-26-234857 · ownership.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,383 F1 · shares: On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. Read SEC document
June 20, 2025 Filed Jun 24, 2025 21:50 UTC	uniQure N.V. QURE · Entity 4162	SaleOrdinary Shares	2,112	$14.45	$30,518.40	Disclosure SEC source: 0000904454-25-000334 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,346 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.50. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:55 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	15,630	$0.00 Strike: $16.22	$0.00	Disclosure SEC source: 0000904454-25-000314 · edgar.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,630 Underlying: Ordinary Shares · 15,630 shares Expires 2035-06-11 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
June 11, 2025 Filed Jun 13, 2025 20:55 UTC	uniQure N.V. QURE · Entity 4162	GrantOrdinary Shares	7,970	$0.00	$0.00	Disclosure SEC source: 0000904454-25-000314 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,458 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
May 30, 2025 Filed Jun 2, 2025 20:30 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock options (right to buy) · Derivative	16,000	$0.00 Strike: $7.42	$0.00	Disclosure SEC source: 0000950170-25-080308 · ownership.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-05-30 F3 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document
May 30, 2025 Filed Jun 2, 2025 20:30 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantCommon Stock, par value $0.0001 per share	4,800	$0.00	$0.00	Disclosure SEC source: 0000950170-25-080308 · ownership.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,583 F1 · shares: On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F2 · balance_after: This amount includes 4,800 unvested RSUs that were granted on May 30, 2025. Read SEC document
June 19, 2024 Filed Jun 21, 2024 20:57 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	15,840	$0.00 Strike: $4.57	$0.00	Disclosure SEC source: 0000904454-24-000395 · edgar.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,840 Underlying: Ordinary Shares · 15,840 shares Expires 2034-06-19 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
June 19, 2024 Filed Jun 21, 2024 20:57 UTC	uniQure N.V. QURE · Entity 4162	GrantOrdinary Shares	8,080	$0.00	$0.00	Disclosure SEC source: 0000904454-24-000395 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,488 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
June 13, 2024 Filed Jun 17, 2024 22:42 UTC	uniQure N.V. QURE · Entity 4162	SaleOrdinary Shares	2,221	$5.14	$11,415.94	Disclosure SEC source: 0000904454-24-000362 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,408 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.10 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
May 30, 2024 Filed Jun 3, 2024 20:29 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantCommon Stock, par value $0.0001 per share	2,783	$0.00	$0.00	Disclosure SEC source: 0000950170-24-068014 · ownership.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 F1 · shares: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. F1 · balance_after: On May 30, 2024, 2,783 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. Read SEC document
May 16, 2024 Filed May 20, 2024 20:58 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option (right to buy) · Derivative	2,783	$0.00 Strike: $45.92	$0.00	Disclosure SEC source: 0001209191-24-005674 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,783 Underlying: Common Stock · 2,783 shares Expires 2034-05-16 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant. Read SEC document
April 26, 2024 Filed May 1, 2024 01:45 UTC	Akari Therapeutics Plc AKTX · Entity 7692	GrantOrdinary Shares, par value $0.0001 per share	479,569,892	$0.00	$0.00	Disclosure SEC source: 0000950170-24-050854 · ownership.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,018,027,792 F1 · shares: These shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive one ordinary share, par value $0.0001. 50% of the RSUs shall vest on March 28, 2025, with the remainder vesting in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document
June 16, 2023 Filed Jun 20, 2023 21:33 UTC	uniQure N.V. QURE · Entity 4162	SaleOrdinary Shares	2,301	$18.76	$43,166.76	Disclosure SEC source: 0000904454-23-000404 · edgar.xml · nonDerivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,629 F3 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.74 to $18.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 13, 2023 Filed Jun 20, 2023 21:33 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	17,060	$0.00 Strike: $20.18	$0.00	Disclosure SEC source: 0000904454-23-000404 · edgar.xml · derivative · entry 3 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,060 Underlying: Ordinary Shares · 17,060 shares Expires 2033-06-13 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
June 13, 2023 Filed Jun 20, 2023 21:33 UTC	uniQure N.V. QURE · Entity 4162	GrantOrdinary Shares	8,700	$0.00	$0.00	Disclosure SEC source: 0000904454-23-000404 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,930 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
May 18, 2023 Filed May 22, 2023 20:27 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option (right to buy) · Derivative	5,300	$0.00 Strike: $9.96	$0.00	Disclosure SEC source: 0001209191-23-031467 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2033-05-18 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant. Read SEC document
February 27, 2023 Filed Mar 1, 2023 21:11 UTC	uniQure N.V. QURE · Entity 4162	SaleOrdinary Shares	384	$20.02	$7,687.68	Disclosure SEC source: 0000899243-23-006575 · doc4.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,230 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.01 to $20.03. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:03 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	17,810	$0.00 Strike: $14.08	$0.00	Disclosure SEC source: 0000904454-22-000364 · edgar.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
June 15, 2022 Filed Jun 17, 2022 21:03 UTC	uniQure N.V. QURE · Entity 4162	GrantOrdinary Shares	9,080	$0.00	$0.00	Disclosure SEC source: 0000904454-22-000364 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,614 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
May 18, 2022 Filed May 19, 2022 18:41 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	79,600	$0.00 Strike: $0.33	$0.00	Disclosure SEC source: 0001209191-22-030447 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,600 Underlying: Common Stock · 79,600 shares Expires 2032-05-18 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
February 24, 2022 Filed Feb 28, 2022 23:10 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	2,645	$0.00 Strike: $16.04	$0.00	Disclosure SEC source: 0000904454-22-000187 · edgar.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
February 24, 2022 Filed Feb 28, 2022 23:10 UTC	uniQure N.V. QURE · Entity 4162	GrantOrdinary Shares	1,534	$0.00	$0.00	Disclosure SEC source: 0000904454-22-000187 · edgar.xml · nonDerivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,534 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document
October 21, 2021 Filed Oct 23, 2021 00:09 UTC	uniQure N.V. QURE · Entity 4162	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $28.24	$0.00	Disclosure SEC source: 0000904454-21-000721 · edgar.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2031-10-21 F1 · derivative.exercise_date: The Stock Option vests over three years, with one-third vesting on the first anniversary of the date of grant and the remainder vesting quarterly on a pro-rata basis during the remainder of the vesting period, provided that the Stock Option shall vest fully no later than the date of the Issuer's 2024 Annual General Meeting of Shareholders, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document
June 17, 2021 Filed Jun 17, 2021 20:42 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option (right to buy) · Derivative	58,200	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0001209191-21-041461 · doc4.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
June 17, 2021 Filed Jun 17, 2021 20:42 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option (right to buy) · Derivative	58,200	$0.00 Strike: $2.07	$0.00	Disclosure SEC source: 0001209191-21-041461 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,200 Underlying: Common Stock · 58,200 shares Expires 2031-06-17 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
March 15, 2021 Filed Mar 15, 2021 09:15 UTC	Viela Bio, Inc. VIE · Entity 141253	Disposition to issuerStock Option (right to buy) · Derivative	7,358	Not disclosed Strike: $48.96	Not disclosed	Disclosure SEC source: 0000899243-21-011496 · doc4.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,358 shares Expires 2030-06-18 F1 · kind: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. Read SEC document
March 15, 2021 Filed Mar 15, 2021 09:15 UTC	Viela Bio, Inc. VIE · Entity 141253	Disposition to issuerStock Option (right to buy) · Derivative	14,716	Not disclosed Strike: $48.96	Not disclosed	Disclosure SEC source: 0000899243-21-011496 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,716 shares Expires 2030-06-18 F1 · kind: Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option. Read SEC document
June 19, 2020 Filed Jun 23, 2020 16:41 UTC	Viela Bio, Inc. VIE · Entity 141253	GrantStock Option (right to buy) · Derivative	14,716	$0.00 Strike: $48.96	$0.00	Disclosure SEC source: 0001209191-20-038485 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,716 Underlying: Common Stock · 14,716 shares Expires 2030-06-19 F1 · derivative.exercise_date: This option grant vests in equal installments of shares on the anniversary date of the grant for the next three years; June 19, 2021, June 19, 2022 and June 19, 2023. Read SEC document
June 19, 2020 Filed Jun 24, 2020 16:47 UTC Amendment	Viela Bio, Inc. VIE · Entity 141253	GrantStock Option (Right to Buy) · Derivative	7,358	$0.00 Strike: $48.96	$0.00	Disclosure SEC source: 0001209191-20-038741 · doc4a.xml · derivative · entry 2 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,358 Underlying: Common Stock · 7,358 shares Expires 2030-06-18 F2 · derivative.exercise_date: This option grant vests on the first anniversary date of the grant. Read SEC document
June 19, 2020 Filed Jun 24, 2020 16:47 UTC Amendment	Viela Bio, Inc. VIE · Entity 141253	GrantStock Option (Right to Buy) · Derivative	14,716	$0.00 Strike: $48.96	$0.00	Disclosure SEC source: 0001209191-20-038741 · doc4a.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,716 Underlying: Common Stock · 14,716 shares Expires 2030-06-18 F1 · derivative.exercise_date: This option grant vests in equal installments of shares on the anniversary date of the grant for the next three years: June 19, 2021, June 19, 2022 and June 19, 2023. Read SEC document
May 20, 2020 Filed May 22, 2020 19:00 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	40,500	$0.00 Strike: $7.30	$0.00	Disclosure SEC source: 0001209191-20-031661 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2030-05-20 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
May 22, 2019 Filed Jun 28, 2019 20:05 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	33,300	$0.00 Strike: $7.31	$0.00	Disclosure SEC source: 0001209191-19-039467 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,300 Underlying: Common Stock · 33,300 shares Expires 2029-05-22 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document
April 05, 2019 Filed Apr 8, 2019 20:41 UTC	Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261	GrantStock Option(right to buy) · Derivative	68,000	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001209191-19-023975 · doc4.xml · derivative · entry 1 Jacques Rachelle Suzanne · CIK 0001772610 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2029-04-05 F1 · security: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.